Is the treatment of WHO category I tuberculosis with 2HRZE/6HE a defensible practice?

International Journal of Tuberculosis and Lung Disease

Volumn 3, Issue 9, 1999, Pages 747-748

  Long, Richard ^a   Scalcini, Marcella ^b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN; THIOACETAZONE;

DRUG EFFICACY; DRUG SENSITIVITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LUNG TUBERCULOSIS; PRIORITY JOURNAL; SHORT SURVEY; SPUTUM SMEAR; WORLD HEALTH ORGANIZATION;

ANTITUBERCULAR AGENTS; DEVELOPING COUNTRIES; DRUG RESISTANCE, MICROBIAL; DRUG THERAPY, COMBINATION; ETHAMBUTOL; HUMANS; ISONIAZID; MYCOBACTERIUM TUBERCULOSIS; PYRAZINAMIDE; RIFAMPIN; STREPTOMYCIN; TUBERCULOSIS, MULTIDRUG-RESISTANT; WORLD HEALTH ORGANIZATION;

EID: 0032835605     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (9)

1. Standardized treatment regimens. In: Maher D, Chaulet P, Spinaci S, Harries A, eds. Treatment of tuberculosis: guidelines for national programmes. 2nd ed. Geneva: WHO, 1997: pp 25-31.
2. Mitchison D A, Nunn A J. Influence of initial drug resistance on the response to short-course chemotherapy of pulmonary tuberculosis. Am Rev Respir Dis 1986; 133: 423-430.
3. East African/British Medical Research Council. Controlled trial of four 6-month regimens of chemotherapy for pulmonary tuberculosis. Second study. Second report. Am Rev Respir Dis 1976; 114: 471-475.
4. East African/British Medical Research Council. Controlled clinical trial of four short-course regimens of chemotherapy for two durations in the treatment of pulmonary tuberculosis. Third study. Second report. Tubercle 1980; 61: 59-69.
5. Iseman M D, Madsen L A. Drug resistant tuberculosis. Clin Chest Med 1989; 10: 341-353.
6. Norval P-Y, San K K, Bakhim T, Rith D N, Ahn D I, Blanc L. DOTS in Cambodia. Int J Tuberc Lung Dis 1998; 2: 44-51.
7. Crofton J, Chaulet P, Maher D, et al. Guidelines for the management of drug-resistant tuberculosis. Geneva: WHO, 1997.
8. Heifets L, Lindholm-Levy P. Dilemmas and realities in the laboratory diagnosis of tuberculosis in low income countries. [Editorial] Int J Tuberc Lung Dis 1999; 3: 88-89.
9. Chaisson R E, Coberly J S, De Cock K M. DOTS and drug resistance: a silver lining to a darkening cloud. [Editorial] Int J Tuberc Lung Dis 1999; 3: 1-3.